BIO-TECHNE Corp 4

Bio-Techne Corp CEO Kim Kelderman was granted 57,590 time-based RSUs and 93,582 performance-based RSUs of common stock as equity compensation on August 17, 2026.

On August 17, 2026, Bio-Techne Corp CEO Kim Kelderman received a significant equity compensation package consisting of 57,590 time-based restricted stock units and 93,582 performance-based restricted stock units, each representing a contingent right to receive one share of Bio-Techne common stock. The awards vest over multiple years, with the time-based RSUs vesting in tranches between 2027 and 2029 and the performance RSUs vesting upon achievement and certification of specified performance goals, primarily in 2029. The filing also lists Kelderman’s existing portfolio of fully exercisable and unexercised stock options and performance/time-based RSUs, but there is no indication of any open market purchases or sales of common stock; all Form 4 transactions are equity awards granted at zero acquisition cost as part of his executive compensation. The overall effect is to increase the CEO’s future equity-based ownership and alignment with shareholders without an immediate cash transaction or change in current beneficial ownership of common shares outstanding.

Filing Facts

CIK

842023

Ticker

TECH

Form

4

Source Type

fda

Accession

0000914190-26-000133

Alert Tier

6